Cytokinetics financials
WebApr 10, 2024 · SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced that Robert I. Blum, President and … WebApr 10, 2024 · Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. About the company Rewards Revenue is forecast to grow 46.65% per year Risk Analysis Negative shareholders equity
Cytokinetics financials
Did you know?
WebMar 31, 2024 · April 10, 2024. Cytokinetics to Participate in the 22nd Annual Needham Virtual Healthcare Conference. SOUTH SAN FRANCISCO, Calif. , April 10, 2024 (GLOBE NEWSWIRE) -- … WebNov 3, 2024 · SOUTH SAN FRANCISCO, Calif., Nov. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the third quarter of 2024. Net loss for the third quarter was $76.1 million, or $0.95 per share, compared to net loss for the third quarter of 2024 of $3.2 million, or $0.05 per share.
WebNov 3, 2024 · Enrollment Complete in Cohort 3 of REDWOOD-HCM; Results Expected in Q1 2024. SOUTH SAN FRANCISCO, Calif., Nov. 03, 2024 (GLOBE NEWSWIRE) -- … WebApr 6, 2024 · CYTK Complete Cytokinetics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
WebApr 12, 2024 · Finally, Truist Financial assumed coverage on Cytokinetics in a report on Tuesday, December 20th. They issued a “buy” rating and a $60.00 price target for the company. One research analyst has ... WebMar 1, 2024 · SOUTH SAN FRANCISCO, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the fourth …
WebApr 2, 2024 · Financials In 2024, Cytokinetics reported revenues of $2.0 million for Q4 and $94.6 million for the full year, compared to $55.6 million and $70.4 million in the same …
Web18 hours ago · Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 04/03/23-4:00PM EST GlobeNewswire 3 Best Stocks to Buy Now, 4/3/2024, According to Top Analysts bittern horningWebJun 27, 2024 · Financials CYTK has a market cap of $4.05bn and a cash balance of $686mn. Research and development expenses for the first quarter 2024 were $45.9 million, while general and administrative... data structures using c reema thareja pdfWebMar 1, 2024 · SOUTH SAN FRANCISCO, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the fourth quarter and full year 2024. Net loss for the fourth quarter was $137.4 million or $1.45 per share and the net loss for the year 2024 was $389.0 million or $4.33 per share. bittern house gatesheadWebCYTK Finanicals Stock Screener Earnings Calendar Sectors Nasdaq CYTK U.S.: Nasdaq Cytokinetics Inc. Watch list Create CYTK Alert After Hours Last Updated: Mar 8, 2024 … bittern information pointWebFeb 6, 2014 · Financial Guidance 2014. Cytokinetics also announced its financial guidance for 2014. The company anticipates cash revenue will be in the range of $19 to $21 million, cash R&D expenses will be in ... data structures using c reema thareja amazonWebMar 24, 2024 · CYTOKINETICS, INCORPORATED : Forcasts, revenue, earnings, analysts expectations, ratios for CYTOKINETICS, INCORPORATED Stock CYTK US23282W6057 data structures using c tenenbaumWebCYTK Cytokinetics Inc. Annual Income Statement - WSJ Subscribe Sign In Cytokinetics Inc. CYTK (U.S.: Nasdaq) View All companies AT CLOSE 4:00 PM EDT … bittern house